Arcutis Biotherapeutics (ARQT) Net Margin (2022 - 2026)
Arcutis Biotherapeutics (ARQT) posted quarterly Net Margin of 10.72% for Q1 2026, up 2853.0% year-over-year from 0.36% in Q1 2025, and down 179.92% quarter-over-quarter from 13.41% in Q4 2025.
Arcutis Biotherapeutics (ARQT) Net Margin (2022 - 2026) Analysis & Trends
Arcutis Biotherapeutics' Net Margin history runs 5 years deep, the most recent figure standing at 10.72% for Q1 2026.
- In Q1 2026, Net Margin rose 2853.0% year-over-year to 10.72%; the TTM figure through Mar 2026 stood at 0.58% (up 6154.0% YoY), while the FY2025 annual figure was 4.3%, up 7979.0% from the prior year.
- Net Margin for Q1 2026 stood at 10.72%, down from 13.41% in the prior quarter.
- The five-year high for Net Margin was 13.41% in Q4 2025, with the low at 14856.41% in Q3 2022.
- The 5-year median for Net Margin is 117.47% (2023), against an average of 1494.41%.
- The sharpest annual moves came in 2023 and 2024: Net Margin soared 1473895 bps in 2023, then surged 2466 bps in 2024.
- Arcutis Biotherapeutics' Net Margin stood at 2432.25% in 2022, then jumped by 94 bps to 150.83% in 2023, then surged by 90 bps to 15.55% in 2024, then surged by 186 bps to 13.41% in 2025, then slumped by 180 bps to 10.72% in 2026.
- Business Quant data shows ARQT's Net Margin at 10.72% in Q1 2026, 13.41% in Q4 2025, and 7.47% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 32.99% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 30.23% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 30.33% |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.90% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 30.98% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 12.09% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 12.74% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -3.12% |
| 10 | Arcutis Biotherapeutics | 3.29 Bn | 3.05 Bn | 118.92 Mn | 11.56% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 11.56% |
| Mar 31, 2026 | -10.72% |
| Dec 31, 2025 | 13.41% |
| Sep 30, 2025 | 7.47% |
| Jun 30, 2025 | -19.49% |
| Mar 31, 2025 | -39.25% |
| Dec 31, 2024 | -15.55% |
| Sep 30, 2024 | -92.81% |
| Jun 30, 2024 | -169.59% |
| Mar 31, 2024 | -164.04% |
| Dec 31, 2023 | -150.83% |
| Sep 30, 2023 | -117.47% |
| Jun 30, 2023 | -1,488.28% |
| Mar 31, 2023 | -2,880.26% |
| Dec 31, 2022 | -2,432.25% |
| Sep 30, 2022 | -14,856.41% |